Homology Medicines Inc
NASDAQ:QTTB

Watchlist Manager
Homology Medicines Inc Logo
Homology Medicines Inc
NASDAQ:QTTB
Watchlist
Price: 3.03 USD 5.21% Market Closed
Market Cap: 37.3m USD

Homology Medicines Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Homology Medicines Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Homology Medicines Inc
NASDAQ:QTTB
Net Issuance of Common Stock
$1.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.2B
CAGR 3-Years
3%
CAGR 5-Years
-16%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$2.2B
CAGR 3-Years
-123%
CAGR 5-Years
-191%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$3.5B
CAGR 3-Years
-62%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Homology Medicines Inc
Glance View

Market Cap
37m USD
Industry
Biotechnology

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. The company is headquartered in Bedford, Massachusetts and currently employs 224 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

QTTB Intrinsic Value
3.93 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

Back to Top